Smart Immune’s ProTcell platform enables access to long-lasting, allogeneic T-cell progenitors

Smart Immune is a clinical-stage biotechnology company developing ProTcell, a thymus-empowered cell therapy platform to fully and rapidly re-arm the immune system, enabling next-generation allogeneic T-cell therapies for all. The company was founded in 2017 to help patients with life-threatening diseases such as high-risk blood cancers and primary immunodeficiencies.

Smart Immune’s ProTcell platform, which is already in Phase I/II clinical trials, enables the recovery of a complete immune repertoire in patients fighting cancer and infection. ProTcell introduces potent, allogeneic T-cell progenitors which are then differentiated by the thymus into fully functional T-cells – an ‘off the shelf’ T-cell medicine. Smart Immune’s partners include Memorial Sloan Kettering in New York and Greater Paris University Hospitals (AP-HP).

Smart Immune was co-founded by Marina Cavazzana, Isabelle André and Karine Rossignol at the Imagine Institute in Paris. Based in Paris, in the Paris Biotech Sante Incubator (located within the grounds of Cochin Hospital), Smart Immune has assembled an outstanding group of scientific, technical and clinical experts in lymphoid biology dedicated to changing the future of cellular medicine. Smart Immune has several partnerships with national and international collaborators. We are led by an experienced, multi-disciplinary team with a strong track record of success.